MXOM is an exploration-stage precious metals mining company with four projects in Chihuahua State, Mexico. The company’s properties are located on the prolific Sierra Madre gold belt and are surrounded by a number of successful mines bearing millions of ounces of gold. MXOM has performed sampling and mapping on its properties and preliminary results indicate economic viability of exploiting these sites..... 

The Immune Response Corporation is an immuno-pharmaceutical company focusing on developing products to treat autoimmune and infectious diseases. The company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of Multiple Sclerosis (MS) and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. 

UPSN is an innovative company operating in the rapidly growing mobile search and entertainment sector. The company has been first to mobile search market and pay-per-call advertising and benefits from the potential of an important new advertising driven market for search on mobile phones.  

We are initiating coverage of American Goldfields Inc. (“AGFL”) with a Speculative Buy rating. We also assign a price target of $1 per share of AGFL and plan to revisit the target after the company will publish information on its mineral reserves and operating results for the coming quarter 

Since our initiation of coverage of NAYN, several important events have taken place. Most importantly, the company has commenced commercial operations 

We have initiated coverage with a Buy rating on "CVBT", and assigned a target price of 26.3, determined as the sum of the estimated net present values (NPV) for each potential uses of Cardio Vascu-Grow™, weighted with the estimated chance for Cardio Vascu-Grow™ to be eventually approved for each potential use. 

We beleive EAQU is poised to witness strong growth in the coming quarters through multiple strategic partnerships, including the recent: (1) license agreement with Water Sciences, LLC ; (2) distribution agreement with Hydration Performance Recovery Ltd; (3) business partnership with Robby Gordon Motorsports. 

1.Completion of acquisition of the non-domestic business of Pharma Trials International LLC for $1,500,000 in common stock;2,Agreement with InvaPharm LLC to develop four additional pharmaceutical products;3.Strategic alliance agreement with Telomolecular Corp to develop products that treat aging and age-related diseases;4. A 1.1 to 1 forward stock split of NWLF’s common stock.  

Even with the big losses it incurred, CHRZ remains poised to break even and the recent reorganization initiatives should restore the company’s equilibrium and ultimately increase its profitability. 

The company reported strong revenue and gross margins for Q3FY05, but we are concerned about the following developments which can negatively affect FTG’s stock price and liquidity in the short to medium run....... 

Given the materially adverse business conditions that severely damaged OMNI's third quarter revenue base as they related to Hurricanes Katrina and Rita, which dealt a significant business interruption blow, the third quarter results (3QFY05) were better than expected 

Having invested heavily in product development over the last two years, now comes the time for EPRT to reap the rewards. According to management, during the fourth quarter of 2005, the company will report the first revenue from the sales of its solutions, expecting that in 2006 and 2007 it will generate total sales of about $35 - $40 million. 

We reaffirm our Buy rating and price target on IWTT following Q2FY05 results. We consider that IWTT’s financial performance was marked by favorable developments, among which are: 

We maintain our Buy Rating and price target following management forecast of revenue and earnings for the fiscal years 2005 and 2006. While management projections for FY05 were generally in line with our expectations, the FY06 projections are slightly above our estimates 

PUBC continues to sign up new client companies.Between December 2004 and July 2005, PUBC signed 16 contracts with new clients and is currently working to bring 23 companies to the public markets. 

The sector experienced a double-digit growth close to 40% during 2003 and 2004, powered by the growing number of wireless subscribers, enhanced telecommunications capacities, and significant demand for value-added services. Moreover, the strong growth should continue through... 

We maintain our Speculative Buy rating on SLXI but revise the price target down from $1.83 to $1.24 mainly due to ... 

The company is recovering after a less favorable Q1FY05. Both Q2 and Q3FY05 results were significantly above the respective FY04 results, suggesting that the negative influence of the database theft has dissipated and as a result GWNI has restored and even expanded its customer base... 

A number of recent adverse events triggered the downgrade: first, the resignation of Deloitte Touché Tohmatsu as WDAC’s independent auditor on May 31, 2005; second, the OTC BB delisting due to WDAC’s failure to submit with the SEC their quarterly reports; and third, WDAC’s major shareholder... 

The number of virtual services providers that adhered to VOII’s services platform is continually increasing, while VOII’s international presence is rising. As a result of these developments, we expect VOII to breakeven during... 

Despite a number of recent developments that negatively affected its share price, including the delay of required filings with the SEC and an accounting restatement, we believe that the company remains well positioned to... 

We maintain our neutral rating on VPER following the release of Q1FY05 results. VPER failed to meet our estimates in Q1FY05, falling behind in... 

After yet another quarter of losses, we are maintaining the Neutral rating on MBTG. With decreasing profitability in Q1FY05 compared to Q1FY04 and an increasing... 

We are maintaining our Speculative Buy Rating and the price target of $2.81/share following the Q1FY05 results. OKME’s management’s...  

We reiterate our Speculative Buy rating on IFUE. We remain confident in the long-run success of IFUE’s shares and investors should use...  

Subsequent to CXTI’s release of the Q1FY05 results, we are maintaining our Speculative Buy rating with a...  

Spelman Research discontinues equity coverage on MediaBay, Inc (“MBAY”). The latest...  

We are maintaining our Speculative Buy rating on CTUM following a review of the recently submitted form